8-K: Haemonetics Q1 FY26: Margins Up, Revenue Down

Haemonetics Corporation reported a 4.4% decrease in Q1 FY26 revenue to $321.4 million, while reaffirming its full fiscal year 2026 guidance.

Summary

• Q1 FY26 revenue was $321.4 million, a 4.4% decrease compared to Q1 FY25.
• Organic revenue increased by 0.5%, while organic ex-CSL revenue increased by 12.9%.
• GAAP earnings per diluted share were $0.70, down from $0.74 in Q1 FY25.
• Adjusted earnings per diluted share were $1.10, up from $1.02 in Q1 FY25.
• Gross margin improved significantly to 59.8% (GAAP) and 60.8% (Adjusted) from 52.0% and 55.3% respectively in Q1 FY25.
• Operating income increased to $53.9 million (GAAP) and $77.6 million (Adjusted).
• Cash flow from operating activities was $17.4 million, and free cash flow was $2.5 million.
• The company reaffirmed its fiscal 2026 guidance for total revenue, organic revenue growth, adjusted operating margin (26-27%), adjusted earnings per diluted share ($4.70-$5.00), and free cash flow ($160M-$200M).

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While reported revenue decreased, the underlying organic ex-CSL growth was strong, and profitability metrics (gross margin, adjusted EPS, operating income) showed significant improvement. The reaffirmation of full-year guidance indicates management confidence, offsetting the headline revenue decline which is largely due to divestitures and transitional agreements.

Positives

• Significant improvement in gross margin: GAAP gross margin increased to 59.8% from 52.0%, and adjusted gross margin increased to 60.8% from 55.3%, primarily driven by pricing benefits and product mix.
• Strong organic ex-CSL revenue growth of 12.9%, indicating robust performance excluding the transitional CSL Plasma supply agreement.
• Adjusted earnings per diluted share increased by 7.8% to $1.10, demonstrating profitable growth despite the reported revenue decline.
• Operating income saw substantial growth: GAAP operating income increased by 35.5% to $53.9 million, and adjusted operating income increased by 9.2% to $77.6 million.
• Positive cash flow from operating activities of $17.4 million, a significant improvement from a negative $27.4 million in the prior year.
• Reaffirmation of full fiscal year 2026 guidance, including adjusted operating margin, adjusted EPS, and free cash flow, suggests confidence in future performance.
• Management reported gaining share in Plasma and advancing impact in Hemostasis Management.

Negatives

• Total net revenue decreased by 4.4% to $321.4 million compared to the prior year period.
• GAAP earnings per diluted share decreased by 5.4% to $0.70.
• The Plasma business unit reported a 4.4% decrease in reported revenue and a 4.3% decrease in organic revenue.
• The Blood Center business unit reported a significant 21.7% decrease in reported revenue, primarily due to the divestiture of the Whole Blood product line.
• Cash on hand decreased by $13.9 million since the end of fiscal 2025, primarily driven by cash outflows for strategic investments.
• The income tax rate increased to 25% (GAAP) and 25% (Adjusted) from 18% and 19.9% respectively in the prior year, due to lower benefits from performance share vestings.

Risks

• Availability and demand for the company's products.
• Ability to successfully develop and market new products and technologies.
• Impact of competitive products and pricing.
• Product quality issues.
• Disruptions caused by cybersecurity events.
• Any failure to realize the anticipated strategic benefits and opportunities from acquisitions and divestitures.
• Pricing pressures resulting from trends toward healthcare cost containment and the effect of industry consolidation.
• Manufacturing, distribution, and supply chain disruptions and cost increases.
• Ability to implement as planned and realize estimated cost savings from the market and regional alignment initiative.
• The effects of global economic and political conditions, including changing trade and tariff policies and inflationary pressures.
• Regulatory uncertainties, including in the receipt or timing of regulatory approvals, and the impact of changes in global regulatory conditions.
• Indebtedness incurred by the company, including the conditional conversion feature of its convertible notes.
• The company's ability to protect its intellectual property.
• Litigation.
• The impact of share repurchases on the company's stock price and volatility as well as the effect of short-term price fluctuations on the share repurchase programs effectiveness.

Future Outlook

The company reaffirmed its fiscal 2026 guidance, projecting adjusted operating margin between 26% and 27%, adjusted earnings per diluted share between $4.70 and $5.00, and free cash flow between $160 million and $200 million. Management expects to continue driving meaningful margin expansion, sustaining profitable growth, gaining share in Plasma, advancing in Hemostasis Management, and strengthening commercial execution in Vascular Closure to achieve ambitious long-range plan goals.

Management Comments

• "We are continuing to drive meaningful margin expansion and sustain profitable growth."
• "We are gaining share in Plasma, advancing our impact in Hemostasis Management, and taking decisive steps to strengthen commercial execution in Vascular Closure."
• "We remain well-positioned to achieve our ambitious long-range plan goals."

Industry Context

The medical technology sector, particularly in blood and plasma management, is subject to evolving healthcare cost containment pressures and industry consolidation. Haemonetics' focus on margin expansion and strategic investments in R&D, alongside efforts to gain market share in Plasma and strengthen specific product lines like Vascular Closure, indicates a strategy to navigate these dynamics and maintain competitiveness. The divestiture of the Whole Blood product line reflects a strategic portfolio rationalization, aligning with broader industry trends of companies focusing on higher-growth or higher-margin segments.

Comparison to Industry Standards

• The 12.9% organic ex-CSL revenue growth in Plasma suggests strong underlying demand and market penetration, potentially outperforming some competitors facing similar transitional supply agreement impacts.
• The significant improvement in gross margin (59.8% GAAP, 60.8% Adjusted) driven by pricing benefits and product mix indicates effective cost management and value capture, which could position Haemonetics favorably against peers in terms of profitability.
• The reaffirmed fiscal 2026 guidance, particularly for adjusted operating margin (26-27%) and free cash flow ($160M-$200M), provides a benchmark for evaluating the company's financial health and operational efficiency relative to other medical device companies of similar size and market focus.

Stakeholder Impact

• Shareholders: Potential for increased value through sustained profitable growth, margin expansion, and reaffirmed positive guidance. Share repurchases are mentioned as a risk factor, implying potential impact on stock price.
• Customers: Continued focus on innovative solutions and strengthening commercial execution in areas like Vascular Closure aims to enhance outcomes and service.
• Employees: Increased investments in research and development suggest ongoing innovation and potential for growth opportunities.
• Creditors: Indebtedness and convertible notes are mentioned, indicating ongoing financial obligations.

Next Steps

• Host a conference call with investors and analysts on August 7, 2025, at 8:00 a.m. ET to discuss Q1 FY26 results.
• Continue driving meaningful margin expansion and sustaining profitable growth.
• Continue gaining share in Plasma.
• Continue advancing impact in Hemostasis Management.
• Continue taking decisive steps to strengthen commercial execution in Vascular Closure.
• Work towards achieving ambitious long-range plan goals.

Key Dates

Recommendation

While Haemonetics demonstrated strong underlying organic growth (ex-CSL) and significant margin expansion, the overall reported revenue decline and the impact of the CSL Plasma transitional agreement introduce some near-term uncertainty. The reaffirmation of guidance is positive, but the stock may remain in a 'hold' position as investors await further clarity on the full impact of strategic divestitures and the company's ability to consistently translate improved margins into stronger top-line growth across all segments. The increase in tax rate and decrease in cash on hand due to strategic investments also warrant a cautious approach.

Keywords

Haemonetics, HAE, financial results, Q1 2026, earnings, medical technology, plasma, blood center, hospital, vascular closure, hemostasis management, SEC filing, financial performance, revenue, profit, cash flow, guidance